Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

leukemia, myeloid, accelerated-phase - Clinical Profile, Genes & Research | Kisho | Kisho

19 clinical trials registered, 8 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and procedural interventions. Pipeline includes 9 PHASE2, 5 PHASE1, 1 NA. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06453902](https://clinicaltrials.gov/study/NCT06453902)	TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients	PHASE2	Shenzhen TargetRx Co., Ltd.	RECRUITING
[NCT05794880](https://clinicaltrials.gov/study/NCT05794880)	MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing	NA	Medical College of Wisconsin	RECRUITING
[NCT02727803](https://clinicaltrials.gov/study/NCT02727803)	Personalized NK Cell Therapy in CBT	PHASE2	M.D. Anderson Cancer Center	RECRUITING
[NCT07020533](https://clinicaltrials.gov/study/NCT07020533)	A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant	PHASE1	City of Hope Medical Center	RECRUITING
[NCT01137825](https://clinicaltrials.gov/study/NCT01137825)	Registry of Older Patients With Cancer	—	UNC Lineberger Comprehensive Cancer Center	RECRUITING

68 publications have been identified in PubMed for leukemia, myeloid, accelerated-phase. Research spans Review / Meta-Analysis (28%), Epidemiology / Natural History (19%), and Case Report / Case Series (18%).

Research Type	Count	% of Total
Research summaries	19	28%
Disease patterns and progression	13	19%
Patient case studies	12	18%
Clinical study results	12	18%
Laboratory research	6	9%
Testing and diagnosis research	5

Recent Publications

Cracchiolo MJ (2026). [PMID: 42126094](https://pubmed.ncbi.nlm.nih.gov/42126094/). *Eur J Haematol*. [Review / Meta-Analysis]
Chen EC (2026). [PMID: 42189880](https://pubmed.ncbi.nlm.nih.gov/42189880/). *Clin Cancer Res*. [Clinical Trial Publication]
Achar RK (2026). [PMID: 42156280](https://pubmed.ncbi.nlm.nih.gov/42156280/). *Semin Hematol*. [Review / Meta-Analysis]
Yuan M (2026). [PMID: 41098110](https://pubmed.ncbi.nlm.nih.gov/41098110/). *Haematologica*. [Clinical Trial Publication]
Lee S (2026). [PMID: 42174310](https://pubmed.ncbi.nlm.nih.gov/42174310/). *Ann Hematol*. [Epidemiology / Natural History]
Zarama-Valenzuela Á (2026). [PMID: 42011407](https://pubmed.ncbi.nlm.nih.gov/42011407/). *Rare Tumors*. [Case Report / Case Series]
Schenk T (2026). [PMID: 41535610](https://pubmed.ncbi.nlm.nih.gov/41535610/). *Ann Hematol*. [Epidemiology / Natural History]
Emiliano EG (2026). [PMID: 42142415](https://pubmed.ncbi.nlm.nih.gov/42142415/). *Hematol Transfus Cell Ther*. [Epidemiology / Natural History]
Chauhan P (2026). [PMID: 41936271](https://pubmed.ncbi.nlm.nih.gov/41936271/). *Curr Res Transl Med*. [Diagnostic / Biomarker]
Mauro MJ (2026). [PMID: 41329950](https://pubmed.ncbi.nlm.nih.gov/41329950/). *Blood*. [Review / Meta-Analysis]

Kisho

leukemia, myeloid, accelerated-phase

Overview

Diagnosis

Research Landscape

Recent Publications

Medical References

Questions for Your Care Team

Questions for Your Care Team

leukemia, myeloid, accelerated-phase

Overview

Diagnosis

Research Landscape

Recent Publications

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team